This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

NeoDynamics Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

NeoDynamics wird voraussichtlich ein Umsatzwachstum verzeichnen at 125% per annum.

Wichtige Informationen

n/a

Wachstumsrate der Gewinne

n/a

EPS-Wachstumsrate

Medical Equipment Gewinnwachstum	24.7%
Wachstumsrate der Einnahmen	125.0%
Zukünftige Eigenkapitalrendite	n/a
Analystenabdeckung	Low
Zuletzt aktualisiert	23 Aug 2023

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Is NeoDynamics (NGM:NEOD) In A Good Position To Invest In Growth?

Mar 18

NeoDynamics AB (publ) (NGM:NEOD) Insiders Increased Their Holdings

Dec 03

Gewinn- und Umsatzwachstumsprognosen

OM:NEOD - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (SEK Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2025	89	N/A	N/A	N/A	1
12/31/2024	32	N/A	N/A	N/A	1
3/31/2024	1	-87	-76	-75	N/A
12/31/2023	1	-93	-77	-76	N/A
9/30/2023	1	-101	-85	-84	N/A
6/30/2023	0	-91	-76	-75	N/A
3/31/2023	0	-82	-73	-72	N/A
12/31/2022	0	-75	-66	-64	N/A
9/30/2022	1	-68	-59	-57	N/A
6/30/2022	1	-66	-57	-55	N/A
3/31/2022	2	-67	-52	-50	N/A
12/31/2021	2	-69	-48	-47	N/A
9/30/2021	4	-60	-41	-36	N/A
6/30/2021	6	-54	-54	-47	N/A
3/31/2021	11	-41	-49	-37	N/A
12/31/2020	17	-31	-54	-36	N/A
9/30/2020	20	-26	N/A	N/A	N/A
6/30/2020	22	-24	-46	-24	N/A
3/31/2020	23	-23	N/A	N/A	N/A
12/31/2019	22	-19	-40	-18	N/A
9/30/2019	25	-21	N/A	N/A	N/A
6/30/2019	24	-21	-62	-37	N/A
3/31/2019	26	-20	N/A	N/A	N/A
12/31/2018	25	-18	-46	-21	N/A
12/31/2017	11	-7	N/A	-3	N/A
12/31/2016	8	-8	N/A	-6	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: Unzureichende Daten, um festzustellen, ob das prognostizierte Gewinnwachstum von NEOD über der Sparquote liegt (1%).

Ertrag vs. Markt: Unzureichende Daten, um festzustellen, ob die Gewinne von NEOD schneller wachsen werden als der Markt Swedish

Hohe Wachstumserträge: Die Daten reichen nicht aus, um festzustellen, ob die Einnahmen von NEOD in den nächsten 3 Jahren erheblich steigen werden.

Einnahmen vs. Markt: NEODDie Einnahmen des Unternehmens (125% pro Jahr) werden voraussichtlich schneller wachsen als der Markt Swedish (1.9% pro Jahr).

Hohe Wachstumseinnahmen: NEODDie Einnahmen des Unternehmens (125% pro Jahr) werden voraussichtlich schneller wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: Unzureichende Daten, um festzustellen, ob die Eigenkapitalrendite von NEOD in 3 Jahren voraussichtlich hoch sein wird

This company listing is no longer active

NeoDynamics Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Price target decreased to kr1.10

Recent updates

Nasdaq Stockholm AB Decides the Shares in NeoDynamics Shall Be Given Observation Status

First quarter 2024 earnings released: kr0.058 loss per share (vs kr19.28 loss in 1Q 2023)

Full year 2023 earnings released: kr30.21 loss per share (vs kr62.00 loss in FY 2022)

NeoDynamics AB (publ) to Report Nine Months, 2024 Results on Nov 19, 2024

Insufficient new directors

NeoDynamics AB (publ) Announces CFO Aaron Wong to Leave by End of May 2024

Neodynamics Launches Device Registry in Germany, Cost-Effective Collection of Real-World Data

New major risk - Shareholder dilution

NeoDynamics AB (publ) has completed a Composite Units Offering in the amount of SEK 72.30071 million.

Second quarter 2023 earnings released: kr0.22 loss per share (vs kr0.17 loss in 2Q 2022)

Neodynamics AB Presents Results of Pulse Study At the Annual Congress of the German Society of Senology, Munich

NeoDynamics AB Presents Final Data Set from NeoDynamics' Pulse Study Presented at the SBI Breast Imaging Symposium

Full year 2022 earnings released: kr0.76 loss per share (vs kr1.14 loss in FY 2021)

NeoDynamics AB (publ) to Report Fiscal Year 2023 Results on Feb 16, 2024

NeoDynamics Announces Changes to Board of Directors

NeoDynamics Appoints Matthew Colpoys, to Lead US Operations

Third quarter 2022 earnings released: kr0.12 loss per share (vs kr0.22 loss in 3Q 2021)

Price target decreased to kr1.10

NeoDynamics AB (publ) Appoints Brendan Carney as National Sales Director

Neodynamics AB (Publ) Launches Neonavia Biopsy System Configured with Its Flexipulse Probe in the United States to Support the Diagnosis of Cancer

NeoDynamics AB (publ) to Report Q3, 2022 Results on Nov 17, 2022

NeoDynamics Receives Approval for Its Innovative Pulse Biopsy System Neonavia® from the US Food and Drug Administration, FDA

Second quarter 2022 earnings released: kr0.17 loss per share (vs kr0.30 loss in 2Q 2021)

Neodynamics AB (Publ) Receives Ethical Approval for German Device Registry

Gryningskust Holding AB acquired additional 14.0 % minority stake in NeoDynamics AB (publ) (OM:NEOD).

NeoDynamics AB (publ) Announces Update on the FDA approval process for NeoNavia

First quarter 2022 earnings released: kr0.28 loss per share (vs kr0.29 loss in 1Q 2021)

NeoDynamics AB (publ) to Report Q1, 2022 Results on May 12, 2022

NeoDynamics Files a Registration Application for Its Innovative Pulse Biopsy System NeoNavia in the U.S

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

NeoDynamics AB (publ) to Report Fiscal Year 2021 Results on Feb 16, 2022

NeoDynamics AB to Present Results from the Pulse Study Illustrating the Benefits of the Novel Biopsy Device NeoNavia in Challenging Axillary Lymph Nodes, At the SBI/ACR Breast Imaging Symposium in Savannah, Georgia

Third quarter 2021 earnings released: kr0.22 loss per share (vs kr0.19 loss in 3Q 2020)

Neodynamics Grants A U.S. Patent for Its Biopsy Needle

Second quarter 2021 earnings released: kr0.30 loss per share (vs kr0.18 loss in 2Q 2020)

CFO & Head of Investor Relations Jorgen Vrenning has left the company

First quarter 2021 earnings released: kr0.29 loss per share (vs kr0.41 loss in 1Q 2020)

NeoDynamics AB Presents an Abstract on Pulse Biopsy Data for NeoNavia at the UK Association of Breast Surgeons Conference 2021

Is NeoDynamics (NGM:NEOD) In A Good Position To Invest In Growth?

New 90-day low: kr3.00

Full year 2020 earnings released: kr0.52 loss per share (vs kr1.24 loss in FY 2019)

New 90-day low: kr3.38

New 90-day low: kr3.60

NeoDynamics Will Be Granted Another European Patent for Its Pulse Biopsy Tools

New 90-day low: kr3.75

Insider recently sold kr423k worth of stock

NeoDynamics AB (publ) (NGM:NEOD) Insiders Increased Their Holdings

Third quarter 2020 earnings released: kr0.19 loss per share

NeoDynamics AB (Publ) Wins First UK Order of Pulse Biopsy System Neonavia

NeoDynamics AB (publ) Enters A Scientific Partnership to Evaluate Its Technology Platform in Osteoarthritis

NeoDynamics AB (publ) Announces Executive Changes

NeoDynamics AB (publ) Ready to Launch the New Pulse Biopsy System NeoNavia

New 90-day high - kr3.49

Earnings released

New 90-day high - kr3.37

Gewinn- und Umsatzwachstumsprognosen

Analystenprognosen zum zukünftigen Wachstum

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Wachstumsunternehmen entdecken